National Eye Institute (NEI)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Eye Institute (NEI) sits in the top decile of US sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count).

221 total trials 18 currently recruiting 179 completed early-phase tilt top decile by trial count

National Eye Institute (NEI): 221 sponsored US clinical trials, 18 recruiting.

National Eye Institute (NEI) sponsors 221 registered US clinical trials on ClinicalTrials.gov, 18 of them currently recruiting, and 179 completed. 11 of these trials are in Phase 3-4 (later-stage) and 86 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Age-related Macular Degeneration, with 8 trials.

Top-decile sponsor footprint

National Eye Institute (NEI) ranks in the top decile of sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 68/100

179 of 196 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

221 total, page 5 of 5

COMPLETED

Normal Human Electro-Oculogram

NCT00001610

COMPLETED

Studies of Families With Hereditary Cataracts

NCT00001609

COMPLETED Phase 1

Anti-tac Therapy FOR Uveitis

NCT00001526

COMPLETED Phase 3

Intravenous Immunoglobulin Therapy in Optic Neuritis

NCT00000117

COMPLETED Phase 3

The Effects of Light Reduction on Retinopathy of Prematurity (Light-ROP)

NCT00000156

COMPLETED

Long Term Follow-Up of Diabetic Retinopathy

NCT00001395

COMPLETED

Study of Usher Syndromes, Type 1 and Type 2

NCT00001347

COMPLETED

Diabetic Retinopathy and Visual Function Study

NCT00001346

COMPLETED Phase 3

Herpetic Eye Disease Study (HEDS) II

NCT00000139

COMPLETED Phase 2

Modified Intraocular Lens to Reduce Eye Inflammation After Cataract Surgery in Uveitis Patients

NCT00001311

TERMINATED

Tissue Studies of Human Eye Diseases

NCT00001310

COMPLETED

Study of Eye Tissue for Sarcoidosis

NCT00001278

COMPLETED

Analysis of Eye Tissue

NCT00001224

COMPLETED Phase 2

Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis

NCT00001213

COMPLETED NA

Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) - Outcome Study of Cryotherapy for Retinopathy of Prematurity

NCT00000133

COMPLETED

Visual Stimulus and Eye Movement

NCT00001172

COMPLETED

Gyrate Atrophy of the Choroid and Retina

NCT00001166

COMPLETED

Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens

NCT00001161

COMPLETED

Pigment Dispersion Syndrome With and Without Glaucoma

NCT00001152

COMPLETED

Visual Function and Ocular Pigmentation in Albinism

NCT00001153

COMPLETED

The Contact Lens and Myopia Progression (CLAMP) Study

NCT00009529

← Previous Page 5 of 5

What is open in the National Eye Institute (NEI) pipeline

18 recruiting of 221 indexed (8% open); 179 completed (81%).

Phase mix: 11 late (III/IV) vs 86 early (I/II) (early-phase heavy).

Top condition: Age-related Macular Degeneration (8 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

National Eye Institute (NEI): open-pipeline peers nationwide

Peers matched on 221 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

National Eye Institute (NEI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200250 0%5%10%15%20%25% Total trials Recruiting share National Eye Institute (NEI)Otsuka Pharmaceutical Development & CommercializationFlorida State UniversityPenn State UniversityUniversity of LouisvilleGE HealthcareHealthPartners InstituteOregon Research InstituteArcutis Biotherapeutics
National Eye Institute (NEI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

National Eye Institute (NEI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 221 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

What to do with this National Eye Institute (NEI) page

221 registered trials is a research-attention snapshot, not an endorsement of National Eye Institute (NEI) or any single study.

  • 18 of National Eye Institute (NEI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Age-related Macular Degeneration is the condition National Eye Institute (NEI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Age-related Macular Degeneration trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Eye Institute (NEI) pipeline card: 221 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.